Revvity (RVTY) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates

Analysts project Revvity (RVTY) to report Q3 EPS of $1.14, a 10.9% year-over-year decline, on revenues of $699.98 million, up 2.3%. While the overall EPS estimate saw a minor 0.2% upward revision, segment forecasts indicate strong 12.5% growth in Life Sciences net sales to $338.39 million, offset by a 5.8% decline in Diagnostics net sales to $361.25 million, with Diagnostics organic growth slowing significantly to 0.2%. Despite a recent 13% stock rally, Zacks maintains a #4 (Sell) rank, suggesting potential underperformance.

Analysis

Revvity (RVTY) is projected to report Q3 EPS of $1.14, representing a 10.9% year-over-year decline, despite an anticipated 2.3% revenue increase to $699.98 million. A minor 0.2% upward revision to the consensus EPS estimate over the past 30 days suggests a slight improvement in analyst expectations, a factor empirically linked to short-term stock performance.

Segmental forecasts reveal a divergence: Net Sales for Life Sciences are expected to grow robustly by 12.5% to $338.39 million. In contrast, Net Sales for Diagnostics are projected to decline by 5.8% to $361.25 million, with organic revenue growth in this segment slowing significantly to 0.2% from 5.0% in the prior-year quarter.

Despite these mixed operational signals and a mildly negative per-ticker sentiment, RVTY shares have outperformed, gaining 13% in the past month compared to the S&P 500's 1.1% rise. However, the company holds a Zacks Rank #4 (Sell), indicating a potential for near-term underperformance relative to the overall market.

Key Decisions for Investors

• Investors should closely scrutinize Revvity's actual Q3 earnings report, focusing on the reported organic growth and forward guidance for the Diagnostics segment, given its projected decline and significant slowdown.
• Consider the sustainability of the recent 13% stock rally in RVTY, especially in light of the Zacks #4 (Sell) rank and the operational headwinds in the Diagnostics division.
• Evaluate the extent to which the strong performance in the Life Sciences segment can consistently offset the drag from the Diagnostics business, as this balance will be critical for future growth.